« Return to News | CROs/Service Providers

Ariosa launch Harmony Prenatal Test through LabCorp

Monday, May 14, 2012 01:54 PM

Ariosa Diagnostics, a molecular diagnostics company of San Jose, Calif., has signed a deal with Laboratory Corporation of America Holdings (LabCorp) and Integrated Genetics, to distribute and administer its Harmony Prenatal Test in the U.S. and Canada.

The Harmony Prenatal Test, which detects common fetal trisomies utilizing a directed approach to analyze cell-free DNA (cfDNA) in maternal blood—such as Trisomy 21, associated with Down syndrome—will be offered through LabCorp and will be available at its 1,000+ patient service centers. The test is performed using a simple maternal blood draw taken at a doctor’s office or patient service center and provides the safety of screening tests with accuracy approaching that of invasive testing for common fetal trisomies. The test is available to pregnant women of at least 10 weeks gestational age with a single fetus conceived without the use of an egg donor.

“Ariosa Diagnostics is very excited to announce the official launch of the Harmony Prenatal Test and the agreement with LabCorp, which helps us deliver on the promise of bringing an affordable and accessible prenatal testing option to pregnant women and their physicians,” said Ken Song, MD, CEO at Ariosa Diagnostics. “With enhanced test performance and simplicity, the Harmony Prenatal Test can be reliably incorporated into the management of pregnancies.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.